4 analysts and 7 sector firms examine the Life Science Tools/Medical Laboratories segment in this 44 page report from The Wall Street Transcript.
Order this Report
Investing in Life Science Tools: Tycho Peterson, JPMorgan
Life Science Tools and Diagnostics: Dan Leonard, First Analysis Corporation
Outlook for Medical Labs and Life Sciences: Alastair Mackay, GARP Research & Securities Co.
Diagnostics Industry Progress Investment Highlights: Stephen D. Simpson, Northland Securities
CEO Interviews (average 2,500 words): Top management from 7 sector firms examine the outlook for their firm and sector. Firms interviewed include: Abaxis Inc., Burzynski Research Institute, Beckman Coulter, Inc., Cord Blood America, MedaSorb Technologies Corporation, Micro-Imaging Technology, SeraCare Inc.
Topics covered: Healthcare Reform - Impact of recession - M&A activity - Regulatory developments - Technology advances - Investor issues - Recommended stocks.
ORDER THIS REPORT NOW! CLICK HERE
Companies covered: Affymetrix, AstraZeneca (AZN), Beckman Coulter (BEC), Bio-Rad Laboratories (BIO), Cardiovascular Systems (CSII), Cepheid (CPHD), Gen-Probe (GPRO), ICU Medical (ICUI), Illumina (ILMN), Immucor (BLUD), Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), Life Technologies (LIFE), Luminex (LMNX), Mettler Toledo, Millipore (MIL), Myriad Genetics (MYGN), Pfizer (PFE), Qiagen (QGEN), Thermo, Waters, Zoll Medical (ZOLL).


